Establishment of Pharmaceutical Industry

Posted On: 27 MAR 2026 4:23PM by PIB Delhi The Government has launched the PLI Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (also known as the PLI Scheme for Bulk Drugs) to promote the establishment of new pharmaceutical industrial units. The PLI Scheme for Bulk Drugs has a budgetary outlay of ₹6,940 crore, and it aims to improve self-reliance and reduce import dependence in critical KSMs, DIs and APIs. As of December 2025, 48 greenfield projects have been approved under the scheme with committed investment of ₹4,329.95 crore, against which actual investment of ₹4,814.1 crore has been made. 38 projects have been commissioned, resulting in establishment of domestic manufacturing capacity of approximately 56,800MT per annum. Details of projects approved under PLI Scheme for Bulk Drugs, State-wise and district-wise are placed at Annexure. The Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme has been launched by the Government with an outlay of ₹5,000 crore to transform India’s Pharma MedTech sector including Madhya Pradesh and Dadra and Nagar Haveli, from cost-based to innovation-based growth by strengthening research and to promote industry-academia linkage for research and development in priority areas in drug discovery and development and medical devices. Under this, seven Centres of Excellence (CoEs) have been set up, with total budgetary support to the tune of ₹700 crore, to create research infrastructure and promote R&D in identified areas. The CoEs have so far approved 104 research projects under the scheme and have filed two patents. The scheme also includes an outlay of ₹4,250 crore for support to industry and startups, including in collaboration with academia, for undertaking research and innovation projects in priority areas. The Pradhan Mantri Bhartiya Janaushadhi Pariyojana was launched by the Government of India to make quality generic medicines available at affordable prices for all citizens. Under this scheme, special outlets called Jan Aushadhi Kendras are opened across the country which provide medicines that are about 50% to 80% cheaper than branded medicines, helping reduce healthcare expenses for patients. Under the scheme, 634 JAKs in Madhya Pradesh and 41 JAKs in the Union Territory of Dadra and Nagar Haveli and Daman & Diu have been opened which aim to increase the availability of affordable medicines in Madhya Pradesh and Union Territory of Dadra and Nagar Haveli and Daman & Diu. Further, to increase availability of medicines, Pharmaceutical & Medical Devices Bureau of India (PMBI), which is the implementing agency of the PMBJP scheme, utilises an end-to-end information-technology-enabled supply chain system through which availability of medicines are monitored in these JAKs. The JAKs are incentivised to maintain the stocks of 200 high demand products under the scheme. In addition, 400 fast-moving products are monitored regularly by PMBI with periodic forecasting aided by digital tools. Annexure Details of approved projects under the PLI Scheme for Bulk Drugs, State-wise and district-wise: S. No. Name of the Company Product District Project Location (State) 1. Aurobindo Pharma Limited Through Lyfius Pharma Pvt Ltd. Penicillin G East Godavari Andhra Pradesh 2. Karnataka Antibiotics and Pharmaceuticals Limited 7 ACA Ujjain Madhya Pradesh 3. Kinvan Private Limited Clavulanic Acid Solan Himachal Pradesh 4. Orchid Bio-Pharma Limited 7 ACA Kathua Jammu & Kashmir 5. Macleods Pharmaceutical Limited Rifampicin Bharuch Gujarat 6. Natural Biogenex Private Limited Betamethasone Tumkur Karnataka 7. Natural Biogenex Private Limited Dexamethasone Tumkur Karnataka 8. Natural Biogenex Private Limited Prednisolone Tumkur Karnataka 9. Symbiotec Pharmalab Private Limited Prednisolone Dhar Madhya Pradesh 10. Emmennar Pharma Pvt Ltd. 1,1 Cyclohexane Diacetic Acid (CDA) Sangareddy Telangana 11. Granules India Limited Dicyandiamide (DCDA) Visakhapatnam & Kakinada (2 locations) Andhra Pradesh 12. Hindys Lab Pvt Ltd. 1,1 Cyclohexane Diacetic Acid (CDA) Nalgonda Telangana 13. Meghmani LLP Para Amino Phenol Bharuch Gujarat 14. Sadhana Nitro Chem Ltd. Para Amino Phenol Raigad Maharashtra 15. Alta Laboratories Limited Aspirin Raigad Maharashtra 16. Amoli Organics Private Limited Diclofenac Sodium Valsad Gujarat 17. Anasia Lab Private Limited Losartan Nalgonda Telangana 18. Anasia Lab Private Limited Olmesartan Nalgonda Telangana 19. Andhra Organics Limited Olmesartan Srikakulam Andhra Pradesh 20. Andhra Organics Limited Sulfadiazine Srikakulam Andhra Pradesh 21. Andhra Organics Limited Telmisartan Srikakulam Andhra Pradesh 22. Aviran Pharmachem Private Limited Artesunate Mehsana Gujarat 23. Centrient Pharmaceuticals India Private Limited Atorvastatin Nawanshahr Punjab 24. Dasami Lab Pvt Ltd. Carbamazepine Nalgonda Telangana 25. Dasami Lab Pvt Ltd. Oxcarbazepine Nalgonda Telangana 26. Global Pharma Healthcare Private Limited Ofloxacin Tiruvannamalai Tamil Nadu 27. Globela Industries Pvt Ltd Norfloxacin Bharuch Gujarat 28. Globela Industries Pvt Ltd Ofloxacin Bharuch Gujarat 29. Hazelo Lab Pvt Ltd. Vitamin B6 Yadadri Telangana 30. Hetero Drugs Limited Carbidopa Visakhapatnam Andhra Pradesh 31. Hetero Drugs Limited Levodopa Visakhapatnam Andhra Pradesh 32. Hetero Drugs Limited Levofloxacin Sangareddy Telangana 33. Hetero Drugs Limited Oxcarbazepine Sangareddy Telangana 34. Hindys Lab Pvt Ltd. Acyclovir Nalgonda Telangana 35. Honour Lab Limited Levetiracetam Sangareddy Telangana 36. Honour Lab Limited Lopinavir Visakhapatnam Andhra Pradesh 37. Honour Lab Limited Valsartan Sangareddy Telangana 38. Honour Lab Limited Vitamin B6 Visakhapatnam Andhra Pradesh 39. K P Manish Global Ingredients Pvt Ltd. Artesunate Cuddalore Tamil Nadu 40. Kreative Actives Private Limited Diclofenac Sodium Visakhapatnam Andhra Pradesh 41. MSN Life Sciences Pvt Ltd. Levofloxacin Medak Telangana 42. RMC Performance Chemicals Private Limited Aspirin Jalgaon Maharashtra 43. Sudarshan Pharma Industries Ltd. Vitamin B1 (Chemical Synthesis Route) Raigad Maharashtra 44. Sudarshan Pharma Industries Ltd. Vitamin B6 Raigad Maharashtra 45. Vital Laboratories Private Limited Levofloxacin Valsad Gujarat 46. Vital Laboratories Private Limited Ofloxacin Valsad Gujarat 47. Sustainable Environment Developers Limited Erythromycin Thiocynate (TIOC) SAS Nagar Punjab 48. Orgo Pharma and Fuels LLP 2-Methyl-5Nitro-Imidazole (2-MNI) Yamuna Nagar Haryana This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today. ***** PC/PM (Release ID: 2246061) Visitor Counter : 344 Read this release in: Urdu , हिन्दी Ministry of Chemicals and Fertilizers : Department of Pharmaceuticals Establishment of Pharmaceutical Industry Posted On: 27 MAR 2026 4:23PM by PIB Delhi The Government has launched the PLI Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (also known as the PLI Scheme for Bulk Drugs) to promote the establishment of new pharmaceutical industrial units. The PLI Scheme for Bulk Drugs has a budgetary outlay of ₹6,940 crore, and it aims to improve self-reliance and reduce import dependence in critical KSMs, DIs and APIs. As of December 2025, 48 greenfield projects have been approved under the scheme with committed investment of ₹4,329.95 crore, against which actual investment of ₹4,814.1 crore has been made. 38 projects have been commissioned, resulting in establishment of domestic manufacturing capacity of approximately 56,800MT per annum. Details of projects approved under PLI Scheme for Bulk Drugs, State-wise and district-wise are placed at Annexure. The Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme has been launched by the Government with an outlay of ₹5,000 crore to transform India’s Pharma MedTech sector including Madhya Pradesh and Dadra and Nagar Haveli, from cost-based to innovation-based growth by strengthening research and to promote industry-academia linkage for r